These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9597420

  • 1. Lipoproteins and cardiovascular risk--from genetics to CHD prevention.
    Cullen P, Funke H, Schulte H, Assmann G.
    Eur Heart J; 1998 Apr; 19 Suppl C():C5-11. PubMed ID: 9597420
    [Abstract] [Full Text] [Related]

  • 2. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP, Pépin GM, Mahley RW.
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [Abstract] [Full Text] [Related]

  • 3. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 4. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 5. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ.
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [Abstract] [Full Text] [Related]

  • 6. The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
    Assmann G, Schulte H, Funke H, von Eckardstein A.
    Eur Heart J; 1998 Oct; 19 Suppl M():M8-14. PubMed ID: 9821011
    [Abstract] [Full Text] [Related]

  • 7. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL, Lenz ML, Taylor AA.
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [Abstract] [Full Text] [Related]

  • 8. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM.
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [Abstract] [Full Text] [Related]

  • 9. Role of lipid and lipoprotein profiles in risk assessment and therapy.
    Ballantyne CM, Hoogeveen RC.
    Am Heart J; 2003 Aug; 146(2):227-33. PubMed ID: 12891189
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis and management of new cardiovascular risk factors.
    Cullen P, von Eckardstein A, Assmann G.
    Eur Heart J; 1998 Nov; 19 Suppl O():O13-9. PubMed ID: 9857944
    [Abstract] [Full Text] [Related]

  • 11. Search for an optimal atherogenic lipid risk profile: from the Framingham Study.
    Nam BH, Kannel WB, D'Agostino RB.
    Am J Cardiol; 2006 Feb 01; 97(3):372-5. PubMed ID: 16442398
    [Abstract] [Full Text] [Related]

  • 12. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.
    Am J Cardiol; 2007 Nov 15; 100(10):1499-501. PubMed ID: 17996508
    [Abstract] [Full Text] [Related]

  • 14. Cholesterol: precursor to many lipid disorders.
    Jones PH.
    Am J Manag Care; 2001 Aug 15; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [Abstract] [Full Text] [Related]

  • 15. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
    Ballantyne CM.
    Am Heart J; 2004 Jul 15; 148(1 Suppl):S3-8. PubMed ID: 15211326
    [Abstract] [Full Text] [Related]

  • 16. Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias.
    CMAJ; 1990 Jun 15; 142(12):1371-82. PubMed ID: 2190685
    [Abstract] [Full Text] [Related]

  • 17. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Daskalopoulou SS, Kakafika AI, Pehlivanidis AN, Bouloukos VI, Langer A, GREACE Study Collaborative Group.
    Curr Med Res Opin; 2004 Sep 15; 20(9):1385-92. PubMed ID: 15383187
    [Abstract] [Full Text] [Related]

  • 18. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 15; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 19. [Statins in primary prevention of coronary heart disease].
    Paulweber B.
    Wien Med Wochenschr; 1999 Apr 15; 149(5-6):129-38. PubMed ID: 10408004
    [Abstract] [Full Text] [Related]

  • 20. Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol.
    Grover SA, Dorais M, Coupal L.
    Epidemiology; 2003 May 15; 14(3):315-20. PubMed ID: 12859032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.